These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29521646)

  • 1. Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics.
    Velázquez Vega JE; Brat DJ
    Adv Anat Pathol; 2018 May; 25(3):143-171. PubMed ID: 29521646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker-driven diagnosis of diffuse gliomas.
    Appin CL; Brat DJ
    Mol Aspects Med; 2015 Nov; 45():87-96. PubMed ID: 26004297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular genetics of gliomas.
    Appin CL; Brat DJ
    Cancer J; 2014; 20(1):66-72. PubMed ID: 24445767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular pathways in gliomagenesis and their relevance to neuropathologic diagnosis.
    Appin CL; Brat DJ
    Adv Anat Pathol; 2015 Jan; 22(1):50-8. PubMed ID: 25461780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Testing of Brain Tumor.
    Park SH; Won J; Kim SI; Lee Y; Park CK; Kim SK; Choi SH
    J Pathol Transl Med; 2017 May; 51(3):205-223. PubMed ID: 28535583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
    Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
    Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses.
    Dono A; Vu J; Anapolsky M; Hines G; Takayasu T; Yan Y; Tandon N; Zhu JJ; Bhattacharjee MB; Esquenazi Y; Ballester LY
    J Neurooncol; 2020 Sep; 149(3):463-472. PubMed ID: 33009979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular diagnostics of CNS embryonal tumors.
    Pfister SM; Korshunov A; Kool M; Hasselblatt M; Eberhart C; Taylor MD
    Acta Neuropathol; 2010 Nov; 120(5):553-66. PubMed ID: 20882288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
    Macaulay RJ
    Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular classification of adult gliomas: recent advances and future perspectives.
    Barritault M; Meyronet D; Ducray F
    Curr Opin Oncol; 2018 Nov; 30(6):375-382. PubMed ID: 30148717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Further understanding of the pathology of glioma: implications for the clinic.
    Camelo-Piragua S; Kesari S
    Expert Rev Neurother; 2016 Sep; 16(9):1055-65. PubMed ID: 27228211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers.
    Ichimura K; Narita Y; Hawkins CE
    Acta Neuropathol; 2015 Jun; 129(6):789-808. PubMed ID: 25975377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1.
    Cahill DP; Louis DN; Cairncross JG
    CNS Oncol; 2015; 4(5):287-94. PubMed ID: 26545048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glioma biology and molecular markers.
    Cohen AL; Colman H
    Cancer Treat Res; 2015; 163():15-30. PubMed ID: 25468223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Advances on the Molecular Pathology of Glial Neoplasms in Children and Adults.
    Rodriguez FJ; Vizcaino MA; Lin MT
    J Mol Diagn; 2016 Sep; 18(5):620-634. PubMed ID: 27444975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular classification defines 4 prognostically distinct glioma groups irrespective of diagnosis and grade.
    Mur P; Mollejo M; Hernández-Iglesias T; de Lope ÁR; Castresana JS; García JF; Fiaño C; Ribalta T; Rey JA; Meléndez B
    J Neuropathol Exp Neurol; 2015 Mar; 74(3):241-9. PubMed ID: 25668564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of gliomas: from morphology to molecules.
    Ferris SP; Hofmann JW; Solomon DA; Perry A
    Virchows Arch; 2017 Aug; 471(2):257-269. PubMed ID: 28674742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
    Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities.
    Wood MD; Halfpenny AM; Moore SR
    Diagn Pathol; 2019 Apr; 14(1):29. PubMed ID: 30967140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.